Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Targeted axillary dissection (TAD) emerged as the optimal minimally invasive technique, demonstrating superior diagnostic accuracy over other approaches in patients with node-positive breast cancer ...

Patients with lymph node-positive breast cancer may still avoid extensive axillary surgery if they have clear nodes after systemic therapy, data from a prospective registry showed. Patients with clear ...

Please provide your email address to receive an email when new articles are posted on . Patients with pathologic complete response after neoadjuvant systemic therapy remained disease-free at 5 years ...

This Canadian study included 111 women (median age 63 years), most of whom (90%, n=100) had invasive ductal carcinoma. Over the entire cohort, more than half (54%, n=60) underwent mastectomy and 46% ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...